Reeder 2006.
| Methods |
Study design: randomized, parallel‐group, controlled trial Study site(s): not reported whether single‐ or multi‐center Number randomized (total and per group): 20 participants Unit of randomization (individual or eye): not reported Exclusions after randomization: not reported Losses to follow‐up: not reported Number analyzed (total and per group): not reported Unit of analysis (individual or eye): not reported Reported power calculation? (Y/N): N Reported subgroup analysis? (Y/N): N |
|
| Participants |
Participant characteristics Country: not reported Age (mean ± SD, range): not reported Gender: not reported Inclusion criteria: not reported Exclusion criteria: not reported Equivalence of baseline characteristics? (Y/N): not reported |
|
| Interventions |
Intervention #1: capsule containing flaxseed oil (dose not reported) Intervention #2: omega‐3 supplement containing flaxseed oil and fish oil (TheraTears Nutrition); dose not reported Length of follow‐up: 60 days Notes: none |
|
| Outcomes | Primary and secondary outcome measures not clearly distinguished Specified outcome(s): symptoms of dry eye Adverse events reported? (Y/N): N Measurement time points (specify intervals at which outcomes were assessed): not reported Other issues with outcome assessment (eg, quality control for outcomes, if any): none |
|
| Notes |
Study dates: not reported Funding source(s): not reported Conflicts of interest: not reported Publication language: English Notes: abstract only Registered on clinical trials registry? (Y/N): N |
|
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Method of random sequence generation was not reported |
| Allocation concealment (selection bias) | Unclear risk | Allocation concealment was not reported |
| Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | "Double blind" study, but details of masking were not reported |
| Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | "Double blind" study, but details of masking were not reported |
| Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Numbers randomized to each group, lost to follow‐up, and excluded were not reported |
| Selective reporting (reporting bias) | Unclear risk | No access to study protocol or clinical trials registry |
| Other bias | Unclear risk | This study was published in abstract form only, and an associated publication was not identified |